Published in Circulation on January 19, 1999
Natural statins and stroke risk. Circulation (1999) 2.55
Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis (2008) 1.26
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg (2004) 1.03
Cholesterol and strokes. Cholesterol lowering is indicated for strokes due to carotid atheroma. BMJ (2000) 1.01
Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. J Pharmacol Exp Ther (2009) 0.99
Clinical review: Critical care management of spontaneous intracerebral hemorrhage. Crit Care (2008) 0.96
Serum lipids in young patients with ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry (2000) 0.92
Secondary stroke prevention: patent foramen ovale, aortic plaque, and carotid stenosis. Eur Heart J (2012) 0.91
ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity. J Cereb Blood Flow Metab (2010) 0.84
Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications. Health Serv Res (2012) 0.83
Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. Br J Pharmacol (2001) 0.82
The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study. EBioMedicine (2015) 0.82
Statins for the prevention of stroke: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.82
Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS). Int J Stroke (2013) 0.78
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges. Drugs Aging (2009) 0.77
Antithrombotic Secondary Prevention After Stroke. Curr Treat Options Cardiovasc Med (2002) 0.77
Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis (2009) 0.76
Atorvastatin in stroke: a review of SPARCL and subgroup analysis. Vasc Health Risk Manag (2010) 0.75
Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int J Mol Sci (2016) 0.75
Pre and Post-stroke Use of Statins Improves Stroke Outcome. Indian J Community Med (2014) 0.75
Ischemic Stroke Rate Increases in Young Adults: Evidence for a Generational Effect? J Am Heart Assoc (2016) 0.75
The incidence of stroke and transient ischaemic attacks is falling: a report from the Belgian sentinel stations. Br J Gen Pract (2002) 0.75
Social stratification in the dissemination of statins after stroke in Sweden. Eur J Clin Pharmacol (2012) 0.75
Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med (1983) 25.72
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med (1997) 19.93
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol (1985) 17.42
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare Escherichia coli serotype. J Clin Microbiol (1983) 10.23
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med (1996) 6.92
The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med (1995) 6.49
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med (1991) 6.13
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 5.15
Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr (1999) 5.12
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med (1995) 4.94
Escherichia fergusonii and Enterobacter taylorae, two new species of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol (1985) 4.52
Role of iron in the pathogenesis of Vibrio vulnificus infections. Infect Immun (1981) 4.42
TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41
Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33
Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest (1965) 4.23
Myocardial reperfusion: a double-edged sword? J Clin Invest (1985) 4.12
A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med (1980) 3.98
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
Correlation between virulence and colony morphology in Vibrio vulnificus. Infect Immun (1987) 3.93
H7 antiserum-sorbitol fermentation medium: a single tube screening medium for detecting Escherichia coli O157:H7 associated with hemorrhagic colitis. J Clin Microbiol (1985) 3.91
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7. Ann Intern Med (1984) 3.88
Atypical biogroups of Escherichia coli found in clinical specimens and description of Escherichia hermannii sp. nov. J Clin Microbiol (1982) 3.84
Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation (1968) 3.82
A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N Engl J Med (1993) 3.75
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA (1996) 3.69
Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol (1971) 3.68
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med (2001) 3.56
Aortic stenosis. Circulation (1968) 3.49
Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect Immun (1990) 3.47
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 3.39
Non-O group 1 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann Intern Med (1981) 3.25
Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med (1971) 3.24
Characterization of biochemically atypical Vibrio cholerae strains and designation of a new pathogenic species, Vibrio mimicus. J Clin Microbiol (1981) 3.19
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13
Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13
Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr (2001) 3.12
Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis (1998) 3.09
Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 3.07
Mechanism of action of calcium-channel-blocking agents. N Engl J Med (1982) 2.99
Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98
High-molecular-weight plasmid correlates with Escherichia coli enteroinvasiveness. Infect Immun (1982) 2.95
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 2.78
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 2.77
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation (1994) 2.74
Increased pulse pressure and risk of heart failure in the elderly. JAMA (1999) 2.74
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med (1991) 2.68
Comparison of measures of fatty acid intake by subcutaneous fat aspirate, food frequency questionnaire, and diet records in a free-living population of US men. Am J Epidemiol (1992) 2.68
Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst (1994) 2.68
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest (1967) 2.51
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med (1996) 2.49
Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med (1991) 2.49
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47